Home sleep apnea testing miniaturized photoplethysmography. The NightOwl-REI achieved a close correlation and REI-categorization with the MSSS-AHI, especially in light of the significant inter-scorer variability of the analysis of the PSG. 743, after double-labeling near-boundary participants.
812 and the agreement between the ZOL-AHI and MSSS-AHI was. After categorization of the AHI, the agreement between the NightOwl-REI and the MSSS-AHI was. The NightOwl-REI and ZOL-AHI had a correlation of. 001), which was close to the correlation between the ZOL-AHI and MSSS-AHI (ρ =. The NightOwl-REI had a high correlation with the MSSS-AHI (ρ =. The respiratory event index (REI) derived by NightOwl (NightOwl-REI), the apnea-hypopnea index (AHI) derived by Ziekenhuis Oost-Limburg (ZOL-AHI), and the AHI derived by YMT (MSSS-AHI) were compared. (YMT) after analysis by the Michele Sleep Scoring System (MSSS). In order to establish an external benchmark, all PSG tests were edited by a somnologist of Younes Medical Technologies Ltd.
#NIGHTOWL HOME SLEEP TEST SOFTWARE#
The software derives actigraphy from the former, and blood oxygen saturation and peripheral arterial tone, among other features, from the latter.ĭata of 101 participants who underwent an in-laboratory polysomnography (PSG), while wearing the NightOwl sensor, were collected. The sensor acquires accelerometer and photoplethysmographic data. The system consists of a sensor placed on the fingertip and a cloud-based analytics software. Kristin Deuber, +1 614.975.4186, Benjafield AV et al.The objective of this study was to evaluate the performance of a miniaturized home sleep apnea test, called NightOwl. The transaction is not material to ResMed's consolidated financial results its financial terms were not disclosed.
"It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don't even know it."Įctosense will operate within ResMed's Sleep and Respiratory Care business. "ResMed has the global reach and passionate ambition to help increase patient access to Ectosense's proven diagnostic solution and a path to better sleep and overall health," said Frederik Massie, chief technology officer and cofounder of Ectosense. We're excited to welcome Ectosense's life-changing team to the ResMed family." "Ectosense's clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. "In developing markets, we need to make sleep tests affordable, accessible and easy to use," said Justin Leong, ResMed president of Asia and Latin America.
#NIGHTOWL HOME SLEEP TEST ACTIVATION CODE#
2 Digital health solutions help patients stay on sleep apnea therapy once they start (up to 87% are adherent on connected solutions). The NightOwl home sleep test includes: A disposable NightOwl sensor and 10 finger wraps An activation code to access the NightOwl companion app A detailed sleep report manually reviewed by a sleep physician and, if you suffer from severe sleep apnea, a telephone. For millions of people, their best night's sleep must start with a diagnosis."Īn estimated 936 million people worldwide have sleep apnea, 1 and over 80% remain undiagnosed. "We believe Ectosense's digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. "Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea," said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. ResMed has distributed NightOwl in Australia, New Zealand, and India since 2020 under the brand "ResMed onesleeptest™," and has been a minority investor in Ectosense since July 2020. World’s smallest home sleep apnea test, the Night Owl is the size of your fingertip and weighs in at 1 ounce. OctoResMed today has completed the acquisition of Ectosense, a leader in cloud-connected home sleep test (HST) devices that can help millions of people with undiagnosed sleep apnea get the treatment they need - and raise general awareness of the disease.Įctosense's FDA-approved NightOwl™ is sold in the United States, Australia, New Zealand, India, and parts of Europe. Ectosense's NightOwl™ is a leading FDA-approved cloud-connected home sleep apnea test
0 kommentar(er)
